Overview
NICE is unable to make a recommendation about the use in the NHS of empagliflozin (Jardiance) for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim did not provide an evidence submission.
Last reviewed: 12 September 2024
Next review: We will review this decision if the company decides to make a submission.